Navigation Links
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
Date:11/9/2011

THE WOODLANDS, Texas, Nov. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center will be presenting data from Lexicon's LX2931 Phase 2 proof-of-concept clinical trial at the annual meeting of the American College of Rheumatology on Wednesday, November 9, 2011 in Chicago, Illinois.  LX2931 is an orally-administered small molecule designed to inhibit sphingosine-1-phosphate lyase (S1P), an enzyme in a pathway known to be important in regulating the immune response.  

Results from the Phase 2a study demonstrated a favorable safety profile at all doses tested and suggested that patients with rheumatoid arthritis treated with 150 mg of LX2931 once daily showed improvement in the primary efficacy endpoint of the study, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
2. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
3. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
4. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
5. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
6. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
7. Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Foundation Health Care  (FDNH), which owns and operates ... today it will present at the LD Micro Invitational ... Sunset Boulevard Hotel, Los Angeles, CA. ... nd at 3:00pm and will also be available ... contact LD Micro. For more information about the conference, ...
(Date:5/27/2015)... May 27, 2015  Abaxis, Inc. (NasdaqGS: ABAX ... systems, announced today that Ross Taylor , vice ... the role of chief financial officer effective August 1, ... Conference on Thursday, June 4, 2015 at 10:00 a.m. ... Hyatt in New York City . ...
(Date:5/27/2015)... N.J. , May 27, 2015  IGI Laboratories, ... -based specialty generic pharmaceutical company, today updated its ... Second Quarter and Full Year 2015 Updated Financial ... months ended June 30, 2015 are still expected to ... improvement quarter over quarter in total revenue for the ...
Breaking Medicine Technology:IGI Laboratories Updates Business Outlook 2IGI Laboratories Updates Business Outlook 3
(Date:5/27/2015)... 2015 Genius Monkey is pleased to ... marketing technology, they have boosted sales for the Utah ... regional level for seven Utah-based dealers. , Until ... and radio media. In 2014 the Utah Honda dealers ... Genius Monkey , shifted their marketing campaigns more ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 “Heroin has never ... where our overdoses are coming from,” says Harford County Sheriff ... on May 8th. In the surging heroin related incidents in ... for prevention education to prevent heroin addiction and subsequent abuse ... possession charge. Drug Rehab Baltimore is a drug and alcohol ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 SmarterSkin, http://www.smarterskindermatology.com ... with a cutting-edge test that makes it easier for patients ... skin type. , Dr. Sejal Shah is a cosmetic ... in NYC to offer the test. This revolutionary DNA test ... associated with skin aging: , 1. Firmness and ...
(Date:5/27/2015)... May 27, 2015 Holly CaSaroll, founder of ... preventing burns, aging and cancer. The skin is the body’s ... Every year more than 3.5 million cases of skin cancer ... are caused by the sun's ultraviolet rays (UVR). , ... , 1. Avoid the sun between the hours ...
(Date:5/27/2015)... Louisville, KY (PRWEB) May 27, 2015 ... or worse because of lack of compliance documentation or ... a recycler in Miami, a propane gas company in ... doling out fines for incidents and accidents due to ... System (LMS) is proud to introduce the new ...
Breaking Medicine News(10 mins):Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2Health News:In Recognition of National Melanoma Awareness Month, Beauty Guru Details Skin Tips to Prevent Cancer and Premature Aging 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 3
... (December 7, 2010 at 7:30am) The John Theurer ... important research findings presented at the annual meeting of ... 4-7, 2010 in Orlando, Florida. The ASH meeting is ... researchers. Research highlights from the 40 abstracts ...
... Patients who are starting dialysis too early are at ... CMAJ ( Canadian Medical Association Journal ) ... rate (eGFR) is a test that describes the flow ... associated with early dialysis initiation. Current guidelines in the ...
... HealthDay Reporter , MONDAY, Dec. 6 (HealthDay News) -- ... depression, antidepressant prescription rates have continued to climb ... is an encouraging trend as it suggests that fewer ... Dr. Mark Olfson, a professor of clinical psychiatry at ...
... In research to be presented at the American Society ... in Boston offer a new explanation of why chronic lymphocytic ... bone marrow after being cleared from the bloodstream by chemotherapy. ... on Monday, Dec. 6, at 4:45 p.m. in room 315 ...
... WHAT: The costly, time-consuming process of making, distributing and ... obsolete if researchers could design a vaccine that ... Making such a universal influenza vaccine is feasible ... fronts, including finding new ways to evaluate the ...
... Dec. 6 (HealthDay News) -- People with depression who ... believing others are plotting against them, are less likely ... It also found that bipolar disorder does not appear ... depression, a finding that challenges the common theory that ...
Cached Medicine News:Health News:John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers 2Health News:John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers 3Health News:John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers 4Health News:John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers 5Health News:John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers 6Health News:John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers 7Health News:Antidepressant Use Rising as Psychotherapy Rates Fall 2Health News:Antidepressant Use Rising as Psychotherapy Rates Fall 3Health News:Study identifies drug resistance of CLL in bone marrow and lymph nodes 2Health News:A flu vaccine that lasts 2Health News:Depression With Psychotic-Like Symptoms Seems Tougher to Treat 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Steroid-eluting, screw-in pacing lead...
... one of the world's thinnest, ... a 7 F introducer, the ... designed to lower the incidence ... introduction in smaller, more tortuous ...
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
Medicine Products: